Registry-listed formulations

L-serine · chembl:CHEMBL11298

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Serine（Oral）Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(10%)
Results Posted
300%(3 trials)
Terminated
2(20%)

Phase Distribution

Not Applicable
2
20%
Phase 1
1
10%
Phase 3
2
20%
Phase 2
3
30%
Phase 1/2
2
20%

Phase Distribution

1

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 1/2Combined phases
2(20.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
2(20.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(1)
Terminated(3)
Other(3)

Detailed Status

unknown3
Terminated2
Not yet recruiting2
Completed1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 1/22 (20.0%)
Phase 23 (30.0%)
Phase 32 (20.0%)
N/A2 (20.0%)

Trials by Status

terminated220%
completed110%
recruiting110%
unknown330%
withdrawn110%
not_yet_recruiting220%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_3

TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

NCT07377032
not_yet_recruitingphase_3

Study of Serine Supplementation to Protect Vision in MacTel

NCT07342439
not_yet_recruitingphase_1

Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs

NCT07178613
terminatedphase_2

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03580616
terminatedphase_2

Phase IIa L-serine Trial for eAD

NCT03062449
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07377032Phase 3

TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

Recruiting
NCT07342439Phase 3

Study of Serine Supplementation to Protect Vision in MacTel

Not Yet Recruiting
NCT07178613Phase 1

Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs

Not Yet Recruiting
NCT03580616Phase 2

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
NCT03062449Phase 2

Phase IIa L-serine Trial for eAD

Terminated
NCT06113055Phase 2

Hereditary Sensory Neuropathy Serine Trial

Unknown
NCT04646447Not Applicable

Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy

Unknown
NCT01733407Phase 1/2

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

Completed
NCT02528994Not Applicable

Short Term Dietary Serine Supplementation and Circulating Serine Levels

Withdrawn
NCT01835782Phase 1/2

Determining the Safety of L-serine in ALS

Unknown

All 10 trials loaded

Drug Details

Intervention Type
Varies by study
Molecule Type
Small molecule
Total Trials
10

External References

ChEMBL
CHEMBL11298

Names & Codes

Research Codes

NSC-118365